Fresenius Medical Care Korea said Wednesday that it has appointed Kim Hee-gyeong as the new chief executive officer effective on April 1. Fresenius Medical Care is a pharmaceutical company that specializes in dialysis and the treatment of kidney disease and failure, hemodialysis, and peritoneal dialysis.
New CEO Kim is an expert with extensive experience in the domestic and foreign healthcare and medical device industries, the company said.
|CEO Kim Hee-gyeong of Fresenius Medical Care Korea|
Kim has worked in Johnson and Johnson Medical Korea and Johnson & Johnson Vision Care Korea for 16 years. She also has worked at various positions of sales and marketing, leading the growth of these organizations.
In 2014, Kim became the CEO of Johnson & Johnson Vision Care Korea. In 2018, she was appointed to head Johnson and Johnson Vision Care China and strengthened the company’s capability in big data and electronic commerce sectors through beefing up ties with external partners.
She holds a master’s degree in business administration at Yonsei University in Seoul.
“We are confident that the new CEO Kim Hee-gyung's proven record of success and leadership will contribute to lead FMCK to the next level,” said Jean DeSombre, Fresenius Medical Care Asia Pacific’s executive vice president for North Asia.
<© Korea Biomedical Review, All rights reserved.>